Compound Radar

CareDx, Inc. (CDNA) Stock Analysis

Price $50.31
Market cap $2.60B
Next earnings Nov 3, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

73
73/100 High Quality
  • Financial Health 70
  • Profitability 80
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 70

Why this rating?

Health 73/100 — High Quality

Strongest Profitability 80/100
Softest Balance Sheet 65/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

CareDx, Inc. (CDNA) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates CareDx, Inc. 73/100 (High Quality) due to high business quality, strong revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Adequate
  • Valuation Elevated

Financial highlights

Valuation

  • P/E 24.19
  • Forward P/E 37.87
  • EV/Revenue 4.97

Profitability

  • Revenue Growth 52.2%
  • Gross Margin 70.6%
  • Operating Margin 0.2%
  • Net Margin 24.2%
  • ROE 29.5%

Financial strength

  • Cash $373.64M
  • Debt $19.25M
  • Net Cash $354.39M
  • Free Cash Flow $35.44M
  • Current Ratio 4.58

Similar companies

Peers in Diagnostics & Research, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Diagnostics & Research →

FAQ

How Compound Radar scores and tracks CareDx, Inc. (CDNA).

View Methodology & FAQ →